Max Healthcare Q1 FY27: Growth holds steady as new beds and acquisitions reshape the mix

Max Healthcare reported a strong start to FY27, with network gross revenue rising to INR 2,982 crore in Q1 FY27, up 16% year-on-year. Network operating EBITDA grew 15% year-on-year to INR 704 crore, while network PAT increased 3% year-on-year to INR 357 crore. The quarter showed resilient operating momentum, supported by higher occupied bed days, steady occupancy, and a gradual improvement in ARPOB.

At the same time, the quarter also reflected the transition costs of expansion. Operating margin stood at 24.8%, broadly stable versus Q1 FY26 but lower than Q4 FY26, as newly commissioned brownfield capacity and the acquisition of Kalinga Hospital (now MSSH Bhubaneswar) added costs ahead of full utilisation.

Operating engine: volumes up, pricing steady

The core hospital network delivered a 10% year-on-year increase in occupied bed days, while average occupancy remained at 75% despite a meaningful increase in operational bed capacity over the last 12 months. ARPOB for the quarter came in at INR 81.9k, up 5% year-on-year. Outpatient consults were about 10.5 lakh, up 12% year-on-year, indicating that demand creation and referral flows remain healthy.

The company also highlighted two demand levers that continue to expand: international patients and digital-led acquisition. International patient revenue was INR 247 crore in Q1 FY27, up 18% year-on-year and about 9% of hospital revenue. Digital revenue from online marketing activities, web-based appointments and digital lead management was reported at INR 941 crore, about 32% of gross revenue.

A notable mix shift during the quarter was in oncology. Max disclosed that discontinuation of select high value chemotherapy drugs for institutional patients led to a drop in oncology share of inpatient revenues to 22.2% from 25.7% in Q1 FY26. Management stated on the concall that oncology should start to normalise from Q3 onwards and be fully normalised by Q4.

Financial snapshot and cash flow conversion

The reported growth in revenue and EBITDA remained solid, though profitability was moderated by the early phase of newly commissioned beds and acquisition integration costs. Below the EBITDA line, finance costs and depreciation increased, contributing to slower PAT growth.

Free cash from operations was INR 397 crore in Q1 FY27. Management attributed softer cash conversion versus EBITDA to working capital, citing an increase in receivables and collection lumpiness in CGHS and PSU payments. DSO increased from 87 days to 95 days during the quarter.

Expansion and M&A: near-term ramp, long-dated pipeline

Max’s growth plan continues to combine brownfield expansion, selective acquisitions, and greenfield projects. In Q1 FY27, the company completed two strategic transactions.

First, it acquired a controlling stake of 58.28% in Kalinga Hospital Limited for about INR 298 crore, funded through an external commercial borrowing. The acquired asset is a 250-bed NABH-accredited hospital built on a 10-acre land parcel in Bhubaneswar. For the post-acquisition period in Q1 FY27, MSSH Bhubaneswar contributed INR 19 crore in revenue and about INR 2 crore in EBITDA, with occupancy at 50% and ARPOB around INR 35k. Management described the integration focus as clinician hiring, occupancy improvement, and payor mix enhancement, supported by upgrades in operations, infrastructure and technology. The new HIS was rolled out on August 1.

Second, the company acquired the Class A equity shares of Yerawada Properties Private Limited, providing 100% voting rights and about 50.22% economic interest. Max indicated that it intends to acquire Class B shares progressively based on milestones. The company has received preliminary approval from the local municipal corporation for the proposed 450-bed Pune hospital and building plans are being finalised. On the concall, management indicated commissioning by FY30.

On the brownfield side, Max Smart’s expansion is a near-term driver. 202 beds have been operationalised, and the remaining 198 beds are expected to be handed over during Q2 FY27 for phased commissioning. Management said the opened beds were already running at about 80% occupancy, but also reiterated that profitability typically follows after occupancy ramp-up, with ARPOB and payor mix optimisation taking time.

The board also approved a capex of INR 425 crore for a brownfield tower at MSSH Vaishali, adding 202 beds to its existing 387-bed capacity. Building plans are approved, construction has started, and commissioning is expected in Q4 FY30.

Adjacent businesses: steady growth in Max Lab and Max@Home

Max’s capital-light adjacencies continued to deliver growth. Max Lab reported Q1 FY27 net revenue of INR 58 crore, up 20% year-on-year. The company stated that Max Lab services are available across 60+ cities, offering 2,700+ tests.

Max@Home reported Q1 FY27 gross revenue of INR 78 crore, up 32% year-on-year and 7% quarter-on-quarter. Management attributed the growth to physician and rehab, nursing care and attendants, and transactional services such as sample collection and medicine delivery.

New avenue: medical education

Max’s board granted in-principle approval to enter medical education and set up medical colleges, citing proposed changes by the National Medical Commission. In the concall, management stated that draft regulations may allow for-profit companies to open medical colleges, and highlighted that Max already runs significant DNB training and education programs through its education arm. Management also stated an expectation of ROCE above 25% to 30% and said the initiative would be funded through internal accruals, with commercial operations expected over the next few years.

Takeaways

Q1 FY27 reinforces Max Healthcare’s operating consistency: volume-led growth, stable occupancy, improving ARPOB, and growing international and digital channels. The quarter also reflects the cost of building future capacity, with margins moderated by ramp-up expenses and acquisition integration.

Over the next few quarters, the key monitorables are the pace of profitability improvement from newly commissioned beds, the turnaround trajectory at MSSH Bhubaneswar, and the execution cadence on the longer-dated pipeline such as Pune and Vaishali. The planned entry into medical education adds another strategic layer, but its financial contribution will depend on regulatory clarity and execution timelines.